| Literature DB >> 29316880 |
Fang Hua1,2, Tanya Walsh3, Anne-Marie Glenny3, Helen Worthington4.
Abstract
BACKGROUND: The reporting of randomised controlled trial (RCT) abstracts is of vital importance. The primary objective of this study was to investigate the association between structure format and RCT abstracts' quality of methodology reporting, informed by the current requirement and usage of structure formats by leading general medical/internal medicine journals (secondary objective).Entities:
Keywords: Consort; Editorial policies; Publishing; Randomized controlled trials; Reporting quality; Structured abstracts
Year: 2018 PMID: 29316880 PMCID: PMC5761197 DOI: 10.1186/s12874-017-0469-3
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
The checklist used for assessment of methodology reporting in this study, modified from the CONSORT for Abstracts guidelines
| Items/Supplementary itemsa | Criteria/Contentb |
|---|---|
| 1. Design | Explicit description of the trial design (e.g. parallel, cluster, crossover) |
| 2. Participants | Eligibility criteria for participants |
| 3. Setting | Settings where the data were collected |
| 4. Interventions | Interventions intended for each group |
| 5. Outcome | Clearly defined primary/main outcome(s) for the trial |
|
| When was the primary/main outcome(s) assessed |
|
| The number of described primary/main outcome(s) |
| 6. Random assignment | Clear statement that participants were allocated to groups in a randomised manner |
|
| Description of the unit of randomisation (e.g. patients, schools, communities) |
| 7. Sequence generation | Method used for random sequence generation |
| 8. Allocation concealment | Method used for allocation concealment |
| 9. Blinding (Masking) | Whether or not participants, caregivers, and those assessing the outcomes were blinded to group assignment |
|
| Generic description only (e.g. single-blind, double-blind) |
CONSORT for Abstracts: the CONSORT (Consolidated Standards of Reporting Trials) extension guidelines for reporting of RCT abstracts [23]
aOnly the scores of main quality items (no.1 to 9) contributed to the primary outcome (overall quality score, range: 0 to 9); supplementary items (5a, 5b, 6a, 9a) were documented for information purposes only
bDetailed scoring criteria are available in the online Appendix
cA continuous variable, not dichotomous
Abstracts of RCTs published in top-50 journals in the ‘Medicine, General and Internal’ category during July–December 2015 - Frequency of structure formats and relevant editorial policiesa by journal (n = 370)
| No. | Journal | N of RCTs identified (%) | Structure format used (%) | Structure format required | Specific instructions for each heading | Word limit | CONSORT for Abstracts endorsement | ||
|---|---|---|---|---|---|---|---|---|---|
| Unstructured | IMRaD | HS | |||||||
| 1 | New England Journal of Medicine | 73 (19.7) | 0 (0.0) | 73 (100.0) | 0 (0.0) | IMRaD | No | 250 | Not mentioned |
| 2 | The Lancet | 53 (14.3) | 0 (0.0) | 53 (100.0) | 0 (0.0) | IMRaD | Yes | 300 | Required |
| 3 | JAMA - Journal of American Medical Association | 38 (10.3) | 0 (0.0) | 0 (0.0) | 38 (100.0) | HS | Yes | 350 | Not mentioned |
| 4 | Annals of Internal Medicine | 7 (1.9) | 0 (0.0) | 0 (0.0) | 7 (100.0) | HS | No | 275 | Not mentioned |
| 5 | BMJ - British Medical Journal | 8 (2.2) | 0 (0.0) | 4 (50.0) | 4 (50.0) | HS | Yes | 400 | Required |
| 6 | PLOS Medicine | 4 (1.1) | 0 (0.0) | 4 (100.0) | 0 (0.0) | IMRaD | Yes | No limit | Not mentioned |
| 7 | JAMA Internal Medicine | 7 (1.9) | 0 (0.0) | 0 (0.0) | 7 (100.0) | HS | Yes | 350 | Not mentioned |
| 8 | BMC Medicine | 6 (1.6) | 0 (0.0) | 6 (100.0) | 0 (0.0) | IMRaD | Yes | 350 | Recommended |
| 9 | Journal of Cachexia Sarcopenia and Muscle | 0 (0) | – | – | – | IMRaD | No | 400 | Not mentioned |
| 10 | Mayo Clinic Proceedings | 2 (0.5) | 0 (0.0) | 2 (100.0) | 0 (0.0) | IMRaD | No | 250 | Not mentioned |
| 11 | Journal of Internal Medicine | 1 (0.3) | 0 (0.0) | 0 (0.0) | 1 (100.0) | IMRaD | No | 250 | Not mentioned |
| 12 | Canadian Medical Association Journal | 1 (0.3) | 0 (0.0) | 1 (100.0) | 0 (0.0) | IMRaD | Yes | 250 | Not mentioned |
| 13 | Medicine (Baltimore) | 42 (11.4) | 42 (100.0) | 0 (0.0) | 0 (0.0) | Not specified | – | 350 | Not mentioned |
| 14 | Annals of Family Medicine | 4 (1.1) | 0 (0.0) | 4 (100.0) | 0 (0.0) | IMRaD | No | 250 | Not mentioned |
| 15 | Translational Research | 2 (0.5) | 2 (100.0) | 0 (0.0) | 0 (0.0) | Unstructured | – | 250 | Not mentioned |
| 16 | American Journal of Medicine | 6 (1.6) | 0 (0.0) | 6 (100.0) | 0 (0.0) | IMRaD | No | 250 | Not mentioned |
| 17 | American Journal of Preventive Medicine | 11 (3.0) | 0 (0.0) | 4 (36.4) | 7 (63.6) | HS | No | 300 | Not mentioned |
| 18 | Medical Journal of Australia | 2 (0.5) | 0 (0.0) | 0 (0.0) | 2 (100.0) | HS | Yes | 250 | Not mentioned |
| 19 | Annals of Medicine | 0 (0) | – | – | – | IMRaD | No | 200 | Not mentioned |
| 20 | Deutsches Arzteblatt International | 5 (1.4) | 0 (0.0) | 5 (100.0) | 0 (0.0) | IMRaD | No | 200 | Not mentioned |
| 21 | Journal of General Internal Medicine | 12 (3.2) | 0 (0.0) | 4 (33.3) | 8 (66.7) | HS | No | 300 | Not mentioned |
| 22 | Preventive Medicine | 8 (2.2) | 0 (0.0) | 7 (87.5) | 1 (12.5) | Unstructured | – | 250 | Not mentioned |
| 23 | European Journal of Internal Medicine | 1 (0.3) | 0 (0.0) | 1 (100.0) | 0 (0.0) | Not specified | – | 250 | Not mentioned |
| 24 | Palliative Medicine | 0 (0) | – | – | – | HS | Yes | Not specified | Not mentioned |
| 25 | Journal of Pain and Symptom Management | 4 (1.1) | 0 (0.0) | 4 (100.0) | 0 (0.0) | IMRaD | No | 250 | Not mentioned |
| 26 | American Journal of Chinese Medicine | 0 (0) | – | – | – | Unstructured | – | 250 | Not mentioned |
| 27 | European Journal of Clinical Investigation | 1 (0.3) | 0 (0.0) | 1 (100.0) | 0 (0.0) | IMRaD | No | 250 | Not mentioned |
| 28 | Current Medical Research and Opinion | 10 (2.7) | 0 (0.0) | 8 (80.0) | 2 (20.0) | HS | Yes | 300 | Not mentioned |
| 29 | Internal and Emergency Medicine | 1 (0.3) | 1 (100.0) | 0 (0.0) | 0 (0.0) | Not specified | – | 250 | Not mentioned |
| 30 | International Journal of Clinical Practice | 5 (1.4) | 1 (20.0) | 4 (80.0) | 0 (0.0) | Not specified | – | Not specified | Not mentioned |
| 31 | QJM - An International Journal of Medicine | 0 (0) | – | – | – | HS | No | 250 | Not mentioned |
| 32 | Pain Medicine | 10 (2.7) | 0 (0.0) | 5 (50.0) | 5 (50.0) | HS | No | 250 | Not mentioned |
| 33 | Journal of Hospital Medicine | 0 (0) | – | – | – | HS | No | 250 | Not mentioned |
| 34 | British Journal of General Practice | 3 (0.8) | 0 (0.0) | 0 (0.0) | 3 (100.0) | HS | No | 250 | Not mentioned |
| 35 | BMJ Open | 21 (5.7) | 0 (0.0) | 2 (9.5) | 19 (90.5) | HS | Yes | 300 | Recommended |
| 36 | American Journal of Managed Care | 5 (1.4) | 0 (0.0) | 0 (0.0) | 5 (100.0) | HS | Yes | 250 | Not mentioned |
| 37 | Polish Archives of Internal Medicine | 0 (0) | – | – | – | IMRaD | No | 250 | Not mentioned |
| 38 | Journal of the Royal Society of Medicine | 0 (0) | – | – | – | HS | No | 300 | Not mentioned |
| 39 | Swiss Medical Weekly | 0 (0) | – | – | – | IMRaD | No | 600 | Not mentioned |
| 40 | Journal of Women’s Health | 2 (0.5) | 0 (0.0) | 2 (100.0) | 0 (0.0) | IMRaD | No | 250 | Not mentioned |
| 41 | Archives of Medical Science | 3 (0.8) | 0 (0.0) | 3 (100.0) | 0 (0.0) | IMRaD | No | 250 | Not mentioned |
| 42 | AMYLOID - Journal of Protein Folding Disorders | 0 (0) | – | – | – | Not specified | – | 200 | Not mentioned |
| 43 | International Journal of Medical Sciences | 4 (1.1) | 0 (0.0) | 4 (100.0) | 0 (0.0) | Not specified | – | Not specified | Not mentioned |
| 44 | Journal of the American Board of Family Medicine | 3 (0.8) | 0 (0.0) | 3 (100.0) | 0 (0.0) | IMRaD | No | Not specified | Not mentioned |
| 45 | Upsala Journal of Medical Sciences | 0 (0) | – | – | – | IMRaD | No | 250 | Not mentioned |
| 46 | Netherlands Journal of Medicine | 0 (0) | – | – | – | IMRaD | Yes | 250 | Not mentioned |
| 47 | Journal of the Formosan Medical Association | 2 (0.5) | 0 (0.0) | 2 (100.0) | 0 (0.0) | IMRaD | Yes | 250 | Not mentioned |
| 48 | Journal of Urban Health | 0 (0) | – | – | – | Unstructured | – | Not specified | Not mentioned |
| 49 | Family Practice | 0 (0) | – | – | – | IMRaD | No | Not specified | Not mentioned |
| 50 | Postgraduate Medicine | 3 (0.8) | 0 (0.0) | 3 (100.0) | 0 (0.0) | IMRaD | No | 300 | Not mentioned |
IMRaD: introduction, methods, results, and discussion format; HS: highly structured format;
CONSORT for Abstracts: the CONSORT (Consolidated Standards of Reporting Trials) extension guidelines for reporting of RCT abstracts [23]
aEditorial policies according to journals’ ‘instructions to authors’ (as of April 2016)
Fig. 1Flow diagram for journal selection. * Thomson Reuters 2014 Journal Citation Report ® Science Edition
Fig. 2Flow diagram for study Part 2. * Journals with at least 1 RCT identified in study Part 1. † 8 abstracts included from each of the 22 IMRaD journals (journal no.1, 2, 6, 8, 10, 11, 12, 14, 16, 20, 22, 23, 25, 27, 28, 30, 40, 41, 43, 44, 47, 50 in Table 2). ‡ 15 abstracts included from each of the 11 HS journals (journal no.3, 4, 5, 7, 17, 18, 21, 32, 34, 35, 36 in Table 2)
Association between quality of methodology reporting, structure formats and potential confounders - Univariable and multivariable generalised estimation equation (GEE) derived coefficients (B) and 95% confidence intervals, with overall quality score (OQS) as the dependent variable and journal as the grouping factor (n = 341 abstracts from 33 journals)
| Univariable | Multivariableb | |||||||
|---|---|---|---|---|---|---|---|---|
| Explanatory variables | Category/unit |
| 95% CI | QICCa |
| 95% CI | ||
|
| IMRaD | Reference | Reference | |||||
| HS | 0.66 | (0.15, 1.16) | 0.011 | 620.2 | 0.54 | (0.06, 1.03) | 0.028 | |
|
| General | Reference | ||||||
| Specialty | −0.30 | (−0.86, 0.25) | 0.285 | 650.3 | ||||
|
| 0.838 | 651.0 | ||||||
| Europe | Reference | |||||||
| North America | −0.16 | (−0.55, 0.22) | 0.408 | |||||
| Asia | −0.28 | (−0.86, 0.31) | 0.353 | |||||
| Oceania | 0.20 | (−0.63, 1.03) | 0.638 | |||||
| Others | −0.23 | (−1.29, 0.84) | 0.677 | |||||
|
| 1 year | 0.09 | (−0.06, 0.25) | 0.224 | 652.7 | |||
|
| Single centre | Reference | Reference | |||||
| Multi-centre | 0.42 | (0.16, 0.68) | 0.002 | 623.9 | 0.36 | (0.08, 0.64) | 0.013 | |
|
| No | Reference | Reference | |||||
| Yes | 0.69 | (0.39, 0.99) | <0.001 | 625.5 | 0.57 | (0.24, 0.90) | 0.001 | |
IMRaD Introduction, methods, results, and discussion format, HS Highly structured format
aQICC, Corrected quasi likelihood under independence model criterion
bFor the final multivariable model, intercept = 3.437, QICC = 580.3
Reporting of each quality item and supplementary item by structure format, presented with unadjusted and adjusted odds ratios (ORs)
| Items/Supplementary items | N (%) | Crude OR | Adjusted OR | ||
|---|---|---|---|---|---|
| Overall | IMRaD | HS | |||
| 1. Design | 120 (35.2) | 54 (30.7) | 66 (40.0) | 1.51 (0.96, 2.36) | 1.51 (0.77, 2.93); 0.228 |
| 2. Participant | 327 (95.9) | 166 (94.3) | 161 (97.6) | 2.43 (0.75, 7.89) | 2.43 (0.80, 7.33); 0.116 |
| 3. Setting | 182 (53.4) | 65 (36.9) | 117 (70.9) | 4.16 (2.64, 6.56) | 4.16 (1.74, 9.97); 0.001 |
| 4. Interventions | 268 (78.6) | 138 (78.4) | 130 (78.8) | 1.02 (0.61, 1.72) | 1.02 (0.64, 1.62); 0.924 |
| 5. Outcome | 177 (51.9) | 72 (40.9) | 105 (63.6) | 2.53 (1.63, 3.91) | 2.53 (1.30, 4.92); 0.006 |
|
| 138 (40.5) | 49 (27.8) | 89 (53.9) | 3.04 (1.94, 4.76) | 3.04 (1.49, 6.19); 0.002 |
|
| 123 (36.1)c | 93 (52.8)c | 30 (18.2)c | 1.87 (0.88, 3.97)f | 1.83 (0.69, 4.87); 0.224 |
| 177 (51.9)d | 72 (40.9)d | 105 (63.6)d | |||
| 41 (12.0)e | 11 (6.3)e | 30 (18.2)e | |||
| 6. Random assignment | 336 (98.5) | 172 (97.7) | 164 (99.4) | 3.81 (0.42, 34.48) | 3.81 (0.47, 30.76); 0.209 |
|
| 246 (72.1) | 141 (80.1) | 105 (63.6) | 0.43 (0.27, 0.71) | 0.43 (0.25, 0.77); 0.004 |
| 7. Sequence generation | 16 (4.7) | 11 (6.3) | 5 (3.0) | 0.47 (0.16, 1.38) | 0.47 (0.10, 2.25); 0.343 |
| 8. Allocation concealment | 7 (2.1) | 5 (2.8) | 2 (1.2) | 0.42 (0.08, 2.19) | 0.42 (0.06, 2.76); 0.366 |
| 9. Blinding (Masking) | 72 (21.1) | 38 (21.6) | 34 (20.6) | 0.94 (0.56, 1.59) | 0.94 (0.42, 2.14); 0.887 |
|
| 57 (16.7) | 28 (15.9) | 29 (17.6) | 1.13 (0.64, 1.99) | 1.13 (0.51, 2.47); 0.765 |
IMRaD Introduction, methods, results, and discussion format, HS Highly structured format
aDerived from GEE analyses adjusting for potential clustering effect among abstracts published in the same journal, with individual quality item as the dependent variable (adequately reported vs. not adequately reported) and journal as the grouping factor;
bA continuous variable, not dichotomous;
cN (%) for category No. = 0; dN (%) for category 1 ≤ No. ≤ 2; eN (%) for category No. > 2;
fDerived from binary logistic regression (reference group: IMRaD format; dependent variable coding: [0] 1 ≤ No. ≤ 2, [1] No. > 2)
A 12-heading HS format recommended for the reporting of RCT abstracts, modified from the original Haynes proposal for structured abstracts [9] and the CONSORT for Abstracts guidelines [23]
| Heading | Content instruction |
|---|---|
| 1. Objective | State the specific objective or question addressed in the trial. If more than one objective is addressed, indicate the primary objective (based on the predetermined primary outcome) and key secondary objectives. |
| 2. Designa | Use the term ‘randomised’ to indicate that this is an RCT; describe explicitly the design of the trial (e.g. parallel group, cluster randomised, crossover, factorial, superiority, equivalence or noninferiority, or a combination of these designs); report the duration of follow-up. |
| 3. Settinga | Provide information about the trial setting, including the level of care (e.g. primary, secondary, tertiary care) and number of participating centres; describe the geographical location if important (e.g. population research in communities). |
| 4. Participants and interventionsb | Provide eligibility criteria for participants (e.g. demographics, clinical diagnosis, comorbid conditions) and details about the interventions for each group (e.g. dose, route and duration of administration, surgical procedure/technique, name of drug, manufacturer of inserted device, main content of education/lifestyle intervention activity); state the number of participants randomised to each group and the unit of randomisation; |
| 5. Main outcome measure(s)c | Clearly state what the primary outcome was (i.e. the predetermined outcome considered of greatest importance and usually the one used in sample size calculation) and when it was assessed; describe key secondary outcome if important, make sure that primary outcome and secondary outcomes are distinguished; if the trial abstract focuses on a secondary outcome, identify both this outcome and the primary outcome. |
| 6. Sequence generationa | Describe the methods used for random sequence generation (e.g. random number table, computer random number generator, coin tossing, minimisation). |
| 7. Allocation concealmenta | Describe the methods used for allocation concealment (e.g. central allocation, sequentially numbered identical containers, sequentially numbered opaque, sealed envelopes); state ‘None’ when no measures were taken to conceal allocation. |
| 8. Blinding (masking) | State the blinded parties among participants, caregivers/personnel, data assessors and data analysts (automatically indicating that those unmentioned parties were not blinded); avoid generic descriptions (e.g. single-blind, double-blind); state ‘None’ if blinding was not used or not possible/appropriate in the trial. |
| 9. Results | Describe the number of participants in each group that were included in the analysis; for the primary outcome, state a result for each group, the estimated effect size and its precision; report any important adverse events (if no adverse events occurred state this explicitly). |
| 10. Conclusions | Give a general interpretation that is consistent with the trial results, with benefits and harms balanced. |
| 11. Trial registrationa | Provide the registration number and name of trial register. |
| 12. Fundinga | Report the source of funding. |
HS Highly structured, CONSORT for Abstracts: the CONSORT (Consolidated Standards of Reporting Trials) extension guidelines for reporting of RCT abstracts [23]
aFor brevity, content under these headings can be written in phrases rather than complete sentences
bTwo Haynes headings 9 are combined together to facilitate the reporting of unit of randomisation and number of randomised participants, for example:
(1) Sixty patients with breast cancer of stage 0 to III were randomly assigned in a 2:1 ratio to receive surgery technique A (A group) or surgery technique B (B group);
(2) Four classes of healthy high school students were randomly allocated to two additional 40-min courses of outdoor activities (intervention group, 2 classes, 60 students) or their usual pattern of activity (control group, 2 classes, 52 students)
cUsing multiple primary outcomes in a trial incurs interpretation problems and is not recommended [59]